ライフサイエンスコーパス: nasal spray

1 dnol 0.25% eye drops and varenicline 0.03-mg nasal spray).

2 d (1:1, etripamil nasal spray 70 mg: placebo nasal spray).

3 idepressant (active comparator) plus placebo nasal spray.

4 antidepressant or antidepressant and placebo nasal spray.

5 o (n = 21); the other 3 received bevacizumab nasal spray.

6 OT does affect behavior when delivered as a nasal spray.

7 d in Europe in 2012 and is administered as a nasal spray.

8 groups achieved higher abstinence rates with nasal spray.

9 MADRS score from baseline favored esketamine nasal spray.

10 absorption of astodrimer sodium 1% antiviral nasal spray.

11 hallenge especially with traditional topical nasal sprays.

12 Either 1) ipratropium bromide nasal spray 0.06% in buffered salt solution, two 42-micr

13 400 mg twice daily), fluticasone propionate nasal spray (200 mug once daily), or oral montelukast (1

14 ndomly assigned to treatment with esketamine nasal spray (56 or 84 mg twice weekly) and an antidepres

15 with AF-RVR were randomized (1:1, etripamil nasal spray 70 mg: placebo nasal spray).

16 t-to-treat analysis, 25 of 30 patients given nasal spray (83.3%) did not require rescue anesthesia.

17 However, the efficacy of esketamine nasal spray administered as monotherapy for patients wit

18 aluated the efficacy and safety of etripamil nasal spray administered, unsupervised in patients with

19 Esketamine nasal spray, administered in conjunction with an oral an

20 cal efficacy and safety profile as a barrier nasal spray against respiratory viral infection in the n

21 re ibuprofen, acetaminophen, and sumatriptan nasal spray, all of which have shown safety and efficacy

22 Long-term use of decongestant nasal spray (alpha adrenergic agonist) causes nasal cong

23 The analysis included claims for naloxone nasal spray among commercially insured patients and Medi

24 pid-acting antidepressants (e.g., esketamine nasal spray and dextromethorphan-bupropion combination)

25 t could provide the basis for a preventative nasal spray and early treatment option for COVID19 and o

26 We analyzed data for sumatriptan succinate nasal spray and zolmitriptan, eletriptan hydrobromide, a

27 er-acting product (lozenge, gum, inhaler, or nasal spray) and extend treatment beyond 12 weeks.

28 ods of intranasal administration (a standard nasal spray, and a nebulizer expected to improve OT depo

29 ive regimen of oral antibiotics, fluticasone nasal spray, and saline rinses.

30 othpastes, mouthwashes, lozenges, throat and nasal sprays, and as biocides.

31 include nicotine chewing gum, skin patches, nasal sprays, and inhalers, as well as pharmacotherapies

32 ith the protocol, refrained from smoking and nasal sprays, and were fully vaccinated against SARS-CoV

33 Tetracaine hydrochloride-oxymetazoline nasal spray appears to provide adequate and safe anesthe

34 Topical intra-nasal sprays are amongst the most commonly prescribed th

35 gonists (e.g., varenicline and simpinicline) nasal sprays are effective for DED.

36 Saline nasal sprays are frequently used in the management of se

37 Corticosteroid nasal sprays are often unsatisfactory because they are i

38 pports the efficacy and safety of esketamine nasal spray as a rapidly acting antidepressant for patie

39 The efficacy and safety of esketamine nasal spray as compared with extended-release quetiapine

40 on mucociliary function of astodrimer sodium nasal spray (AS-NS) were evaluated and compared with oth

41 we have identified a new usage strategy for nasal sprays available over-the-counter, that registers

42 ne hydrochloride-oxymetazoline hydrochloride nasal spray bilaterally with sham injection.

43 e-epinephrine injection with buffered saline nasal spray bilaterally, or (2) a tetracaine hydrochlori

44 subcutaneous dupilumab to mometasone furoate nasal spray compared with mometasone alone reduced endos

45 Astodrimer sodium nasal spray demonstrates an acceptable nonclinical effic

46 n the brain and were achieved using a simple nasal spray device and solution formulation.

47 Use of nasal spray did not result in CP in aerosol levels.

48 therapies, limited to saline irrigation and nasal spray diluents, found that topical diluents were a

49 ry of product characteristics) of esketamine nasal spray (esketamine group) or extended-release queti

50 or placebo (n = 30) plus mometasone furoate nasal spray for 16 weeks.

51 The use of nasal spray for administering OT in behavioral research

52 l trial of ibuprofen followed by sumatriptan nasal spray for children over 12 years of age for those

53 continued clinical development of etripamil nasal spray for self-administration during PSVT in a med

54 of insulin to this brain region, given that nasal sprays for insulin have been marketed notwithstand

55 Nasal spray formulations of naloxone, a mu-opioid recept

56 es for the transdermal nicotine and nicotine nasal spray groups were not significantly different at 6

57 Zolmitriptan nasal spray has a rapid onset of action and high efficac

58 for a variety of reasons, and recently, BZD nasal sprays have been introduced.

59 estions concerning their use of decongestant nasal spray in a questionnaire prior to examination; the

60 pressant efficacy of S-ketamine (esketamine) nasal spray in major depressive disorder (MDD), we perfo

61 have no idea about the efficacy of capsaicin nasal spray in these patients nor about the time interva

62 administration of nicotine via cigarettes or nasal spray in two experimental sessions.

63 rials evaluating conventional corticosteroid nasal sprays in comparable populations.

64 nasal steroid sprays instead of decongestant nasal sprays in our clinic from October, 2011 to Decembe

65 airways, we delivered capsaicin (200 microM) nasal spray into the nares of 20 subjects (10 with aller

66 We report here that capsaicin nasal spray is effective in a broader group of IR than t

67 Also using a drug-free approach, AM-301 nasal spray is forming a thin film barrier on the nasal

68 is a prevalent condition for which capsaicin nasal spray is the most effective treatment.

69 e state's opioid settlement (50 000 naloxone nasal spray kits each year).

70 evaluated and compared with other available nasal sprays-low pH hydroxypropyl methylcellulose (HPMC-

71 as an oral capsule or via tonsillar swab or nasal spray.METHODSViral shedding from the nose, mouth,

72 e (5 mg, n = 4455), and 8 mometasone furoate nasal spray (MFNS; 200 mug daily, n = 2140) SAR or PAR t

73 IU) of oxytocin (n = 45) or placebo (n = 42) nasal spray, morning and night (32 IU per day) for twelv

74 , the median out-of-pocket cost for naloxone nasal spray (n = 202) across Mississippi was $100.00 (ra

75 ngs were randomized 3:1 to astodrimer sodium nasal spray (N = 30) or placebo (N = 10) at an Australia

76 f fluticasone propionate (n = 47) or placebo nasal spray (n = 48) in each nostril once daily for 21 d

77 reated with nicotine patch (n=623), nicotine nasal spray (n=189), bupropion (n=213), or placebo (n=19

78 abstinence rates with either transdermal or nasal spray nicotine.

79 ts have become available, including nicotine nasal spray, nicotine inhaler, and bupropion hydrochlori

80 A nasal spray of ALN-RSV01 or saline placebo was administe

81 We evaluated whether a daily nasal spray of interferon-alpha (IFN-alpha) would reduce

82 Nasal sprays offer potential protection against viruses.

83 We sought to study the effects of capsaicin nasal spray on the afferent innervation of the nasal muc

84 randomly assigned (1:1) to zavegepant 10 mg nasal spray or matching placebo and self-treated a singl

85 zed 1:1 to receive daily 40 000 IU IFN-alpha nasal spray or normal saline placebo.

86 nseling and 8 weeks of therapy with nicotine nasal spray or transdermal nicotine.

87 As such, oral steroids, topical nasal sprays or irrigation, and surgery can be utilized

88 y NAC with 14 days pre-treatment with saline nasal spray (placebo), then NAC with 14 days pre-treatme

89 antidepressant to flexibly dosed esketamine nasal spray plus a newly initiated antidepressant or to

90 h treatment-resistant depression, esketamine nasal spray plus an SSRI or SNRI was superior to extende

91 IFN-alpha nasal spray prophylaxis reduced the incidence of COVID-1

92 Following a 4-week mometasone furoate nasal spray run-in, patients were randomized to commence

93 E formulations in subcutaneous injection and nasal spray such as pain, adverse side effects and poor

94 inactivated influenza vaccines (IIV3) and a nasal spray, tetravalent live-attenuated influenza vacci

95 trivalent influenza vaccine administered by nasal spray to children 15-71 months old.

96 nalogue of single-stranded RNA) or saline by nasal spray to healthy participants without allergy (n =

97 the efficacy, safety, and tolerability of a nasal spray to induce anesthesia of maxillary teeth.

98 se of 40 IU of oxytocin was administered via nasal spray to male individuals with a schizophrenia spe

99 In patients with HHT, a bevacizumab nasal spray treatment of 3 administrations at 14-day int

100 g updates for self-injectable adrenaline and nasal spray use.

101 e the efficacy and safety of etripamil 70 mg nasal spray using a symptom-prompted, repeat-dose regime

102 essed the efficacy and safety of varenicline nasal spray (VNS) for DED treatment.

103 Zavegepant 10 mg nasal spray was efficacious in the acute treatment of mi

104 o-controlled randomized trial with capsaicin nasal spray was performed involving 33 patients with IR

105 Proportion of anesthesia successes for nasal spray was significantly different from the hypothe

106 Astodrimer sodium nasal spray was well tolerated and is a promising innova

107 OC-01 nasal spray was well tolerated and showed a clinically m

108 uency of medication (oral administration and nasal spray) was also evaluated.

109 ministered by metered pump spray; 2) control nasal spray, which consisted of buffered salt solution;

110 y, and timecourse of response for zavegepant nasal spray with placebo in the acute treatment of migra